Weight Reduction Varies for Patients Receiving Semaglutide, Liraglutide
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 13, 2024 -- For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent, dosage, treatment indication, and persistence of coverage, according to a study published online Sept. 13 in JAMA Network Open.
Hamlet Gasoyan, Ph.D., from the Cleveland Clinic in Ohio, and colleagues documented weight loss achieved with injectable forms of semaglutide or liraglutide in a retrospective cohort study. The analyses included 3,389 adults with a body mass index of at least 30.0 kg/m2 who initiated semaglutide or liraglutide for obesity or type 2 diabetes (T2D).
The researchers found that the mean percentage weight change at one year was –5.1 and –2.2 percent with semaglutide and liraglutide, respectively; –3.2 and –5.9 percent for T2D and obesity as treatment indication; and –5.5, –2.8, and –1.8 percent with persistent medication coverage, with 90 to 275 medication coverage days, and with fewer than 90 medication coverage days, respectively. In the multivariable model, associations with achieving 10 percent or greater weight reduction at one year were seen for obesity versus T2D as a treatment indication (adjusted odds ratio [AOR], 2.46), persistent medication coverage versus 90 medication coverage days or 90 to 275 medication coverage days within the first year (AORs, 3.36 and 1.50), high versus low dosage (AOR, 1.58), and female sex (AOR, 1.57).
"Future research should focus on identifying the reasons for discontinuation of medication use and interventions aimed at improving long-term persistent coverage," the authors wrote.
One author disclosed ties to the pharmaceutical industry; a second author disclosed ties to the health insurance industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Adiposity-Linked Breast Cancer Risk Higher for Women With CVD
MONDAY, July 7, 2025 -- Women with cardiovascular disease (CVD) have a substantially higher adiposity-associated risk for breast cancer, according to a study published online July...
Weight Loss Continues Five Years After Tummy Tucks
THURSDAY, July 3, 2025 -- Patients undergoing abdominoplasty experience continued weight loss up to five years postoperatively, according to a study published in the July issue...
2011 to 2023 Saw Increase in Prevalence of Obesity Among Children
WEDNESDAY, July 2, 2025 -- The prevalence of obesity increased among children and adolescents from 2011 to 2023, with the increase most pronounced among Black youths, according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.